T-Cell Changes in Ankylosing Spondylitis During Infliximab Therapy
Author Information
Author(s): Szalay Balázs, Mészáros Gergő, Cseh Áron, Ács Lilla, Deák Magdolna, Kovács László, Vásárhelyi Barna, Balog Attila
Primary Institution: Semmelweis University
Hypothesis
The study aims to assess the phenotype of T-cell subsets in patients with ankylosing spondylitis before and during infliximab therapy.
Conclusion
Infliximab therapy improved the overall condition of patients, but the abnormalities in T-cell prevalence did not disappear.
Supporting Evidence
- The prevalence of Th2 and Th17 cells was higher in AS patients compared to healthy controls.
- Infliximab therapy improved disease activity but did not normalize T-cell prevalence.
- CD4+ and CD8+ cells showed delayed calcium responses during activation in AS patients.
Takeaway
This study looked at how certain immune cells change in people with a disease called ankylosing spondylitis when they take a medicine called infliximab. Even though the medicine helps them feel better, it doesn't fix all the problems with their immune cells.
Methodology
Flow cytometry was used to determine T-cell subsets in peripheral blood and their intracellular signaling during activation in 13 AS patients before and during infliximab therapy.
Limitations
The study had a small sample size and did not assess local immune conditions in affected joints.
Participant Demographics
11 male and 2 female patients with active ankylosing spondylitis, mean age 43.7 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website